SecBot SecBot

ERAS drug pipeline

Erasca, Inc. · 2 rated drugs
$15.11
−3.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 1
Time to market~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030

ERAS-0015 pan-RAS-IN-2 (no INN/generic name assigned) Updated Jul 13

What to watch

ERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

Bull case
  • Phase 1 data shows best-in-class potential, 62% unconfirmed ORR in 2L+ KRAS G12X NSCLC and 57% in pancreatic cancer at RDE, numerically exceeding Revolution Medicines' RMC-6236 on cross-trial comparison
  • Strong analyst consensus: 14 Buy/Strong Buy, 3 Hold, 0 Sell; mean price target $21 (7% upside from $17.90) with targets ranging up to $30
  • Merck (MRK) collaboration validating, Keytruda combination study underway with Merck supplying pembrolizumab at no cost
Bear case
  • Securities class action lawsuit filed alleging misleading statements about preclinical comparisons to RMC-6236 between Jan 2025 and Apr 2026, lead-plaintiff deadline August 10, 2026
  • Revolution Medicines has accused Erasca of patent infringement and trade secret misappropriation regarding ERAS-0015, creating significant IP overhang
  • Stock crashed ~48% in April 2026 after disclosure of a patient death in the Phase 1 trial, safety concerns remain with early-stage data
● neutral
Impact
PhasePhase 1/1b
Time to market5+ years; still in Phase 1/1b first-in-human testing with no registration-enabling plans announced yet

ERAS-4001 Updated Jul 13

What to watch

Watch for Erasca's H2 2026 BOREALIS-1 preliminary data release. ERAS-4001 is a "second shot on goal" after ERAS-0015's strong Phase 1 showing in April 2026. The stock already trades near analyst mean PT of $21 with a massive run-up from 52-week lows, so upside may be partially priced in. The key question is whether early safety/efficacy data can differentiate ERAS-4001 from Revolution Medicines' daraxonrasib (RMC-6236, Phase 3).

Bull case
  • Potential first-in-class and best-in-class profile: ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor that spares HRAS and NRAS, potentially offering a superior therapeutic window over broader pan-RAS inhibitors (source: erasca.com press release).
  • Massive addressable market: RAS/MAPK pathway mutations occur in over 30% of all human cancers, a multi-billion-dollar TAM with significant unmet need (source: koalagains.com analysis).
  • Strong cash runway: $408.5M in cash as of Q1 2026 funds operations into H2 2028, reducing near-term dilution risk (source: Erasca Q1 2026 press release).
Bear case
  • Extremely early stage: ERAS-4001 is in Phase 1 first-in-human testing, no efficacy data in patients yet. Most early-stage oncology drugs fail before reaching registration trials (source: ClinicalTrials.gov NCT07021898).
  • Intense competition: Revolution Medicines' daraxonrasib (RMC-6236) is already in Phase 3 for pancreatic cancer with median PFS of 8.5-8.8 months, and approved KRAS G12C drugs (Amgen's Lumakras, BMS's Krazati) are on the market (source: fiercebiotech.com, ainvest.com).
  • In-licensed, not internally discovered: ERAS-4001 was in-licensed from Medshine Discovery. Erasca laid off 18% of staff to make room for this program, raising questions about internal R&D capabilities (source: fiercebiotech.com).

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ERAS-007A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsPhase 2Completed85Jul 1, 2026
ERAS-007A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesPhase 2Completed101Aug 15, 2025